Interpace Diagnostics Group, Inc.
(NASDAQ : IDXG)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
ESRXExpress Scripts Holding Company
3.67%71.556.0%$335.54m
CERNCerner Corporation
1.24%69.427.4%$163.07m
DGXQuest Diagnostics Incorporated
1.92%98.984.2%$146.00m
LHLaboratory Corporation of America Holdings
2.07%159.062.3%$107.37m
INCRINC Research Holdings, Inc. Class A
0.00%41.053.4%$65.67m
SRCLStericycle, Inc.
1.55%66.886.7%$61.24m
ATHNathenahealth, Inc.
1.62%135.9717.9%$52.98m
MDRXAllscripts Healthcare Solutions, Inc.
3.50%14.659.4%$39.48m
HLSHealthSouth Corporation
1.44%50.119.4%$38.76m
HCSGHealthcare Services Group, Inc.
3.64%52.926.8%$25.87m
OMCLOmnicell, Inc.
3.09%51.7511.4%$13.76m
HMSYHMS Holdings Corp.
2.40%16.671.9%$12.19m
SRCLPStericycle Incorporated Deposit Shs Repr 1/10th 5 1/4 % Mand Conv Pfd Shs Series A
0.48%52.200.0%$3.60m
HSTMHealthStream, Inc.
1.23%22.976.8%$3.37m
CPSIComputer Programs and Systems, Inc.
2.25%29.5533.7%$2.64m

Company Profile

Interpace Diagnostics Group, Inc. engages in the development and commercialization of molecular diagnostic test. It focuses on early detection high potential progresses to cancer. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.